Literature DB >> 16120971

The future of asthma therapy: integrating clinical and experimental studies.

David B Corry1, Farrah Kheradmand.   

Abstract

Asthma is one of the most common, and now most heavily investigated, of modern diseases. Research along two fronts, involving experimental models of asthma and human clinical trials, proceeds in parallel, often with investigators unaware of their counterpart's findings. Here, we review the unique immunological insights into asthma pathogenesis and therapy that may be gained from comparison of human clinical trial results and analogous experimental studies. The pitfalls and benefits of animal models of asthma are discussed, and we briefly review ongoing asthma clinical studies that are based on immunological principals. Finally, we use new insights from human and animal studies to construct a refined immunopathologic disease model that may be of use in designing future experimental and therapeutic studies.

Entities:  

Mesh:

Year:  2005        PMID: 16120971     DOI: 10.1385/IR:33:1:035

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  97 in total

1.  Allergen vaccination with a liposome-encapsulated extract of Dermatophagoides pteronyssinus: a randomized, double-blind, placebo-controlled trial in asthmatic patients.

Authors:  Antonio Basomba; Ana I Tabar; Dolores Hernández F de Rojas; Blanca E García; Remedios Alamar; José M Olaguíbel; Jaime Moscoso del Prado; Santiago Martín; Pilar Rico
Journal:  J Allergy Clin Immunol       Date:  2002-06       Impact factor: 10.793

2.  Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity.

Authors:  Omid Akbari; Gordon J Freeman; Everett H Meyer; Edward A Greenfield; Tammy T Chang; Arlene H Sharpe; Gerald Berry; Rosemarie H DeKruyff; Dale T Umetsu
Journal:  Nat Med       Date:  2002-07-29       Impact factor: 53.440

3.  The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects.

Authors:  J V Fahy; H E Fleming; H H Wong; J T Liu; J Q Su; J Reimann; R B Fick; H A Boushey
Journal:  Am J Respir Crit Care Med       Date:  1997-06       Impact factor: 21.405

4.  Inhibition of allergic inflammation in a murine model of asthma by expression of a dominant-negative mutant of GATA-3.

Authors:  D H Zhang; L Yang; L Cohn; L Parkyn; R Homer; P Ray; A Ray
Journal:  Immunity       Date:  1999-10       Impact factor: 31.745

5.  Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen.

Authors:  O Akbari; R H DeKruyff; D T Umetsu
Journal:  Nat Immunol       Date:  2001-08       Impact factor: 25.606

6.  Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response.

Authors:  L P Boulet; K R Chapman; J Côté; S Kalra; R Bhagat; V A Swystun; M Laviolette; L D Cleland; F Deschesnes; J Q Su; A DeVault; R B Fick; D W Cockcroft
Journal:  Am J Respir Crit Care Med       Date:  1997-06       Impact factor: 21.405

7.  Absence of relationship between tuberculin reactivity and atopy in BCG vaccinated young adults.

Authors:  E Omenaas; H F Jentoft; W M Vollmer; A S Buist; A Gulsvik
Journal:  Thorax       Date:  2000-06       Impact factor: 9.139

8.  Airway epithelial cell expression of interleukin-6 in transgenic mice. Uncoupling of airway inflammation and bronchial hyperreactivity.

Authors:  B F DiCosmo; G P Geba; D Picarella; J A Elias; J A Rankin; B R Stripp; J A Whitsett; R A Flavell
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

9.  IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses.

Authors:  M Kopf; F Brombacher; P D Hodgkin; A J Ramsay; E A Milbourne; W J Dai; K S Ovington; C A Behm; G Köhler; I G Young; K I Matthaei
Journal:  Immunity       Date:  1996-01       Impact factor: 31.745

10.  Identification of A3 receptor- and mast cell-dependent and -independent components of adenosine-mediated airway responsiveness in mice.

Authors:  Stephen L Tilley; Mindy Tsai; Cara M Williams; Z-S Wang; Christopher J Erikson; Stephen J Galli; Beverly H Koller
Journal:  J Immunol       Date:  2003-07-01       Impact factor: 5.422

View more
  3 in total

1.  Proteomic identification of in vivo substrates for matrix metalloproteinases 2 and 9 reveals a mechanism for resolution of inflammation.

Authors:  Kendra J Greenlee; David B Corry; David A Engler; Risë K Matsunami; Philippe Tessier; Richard G Cook; Zena Werb; Farrah Kheradmand
Journal:  J Immunol       Date:  2006-11-15       Impact factor: 5.422

2.  Osteopontin Promotes Protective Antigenic Tolerance against Experimental Allergic Airway Disease.

Authors:  Themis Alissafi; Evangelia Kourepini; Davina C M Simoes; Nikolaos Paschalidis; Maria Aggelakopoulou; Tim Sparwasser; Louis Boon; Hamida Hammad; Bart N Lambrecht; Vily Panoutsakopoulou
Journal:  J Immunol       Date:  2018-01-12       Impact factor: 5.422

Review 3.  Genetic variability of the high-affinity IgE receptor alpha-subunit (FcepsilonRIalpha).

Authors:  Daniel P Potaczek; Chiharu Nishiyama; Marek Sanak; Andrew Szczeklik; Ko Okumura
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.